Bronchodilator Reversibility in COPD

Size: px
Start display at page:

Download "Bronchodilator Reversibility in COPD"

Transcription

1 CHEST Special Features Bronchodilator Reversibility in COPD Nicola A. Hanania, MD, FCCP ; Bartolome R. Celli, MD, FCCP ; James F. Donohue, MD, FCCP ; and Ubaldo J. Martin, MD, FCCP COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The diagnosis of COPD is based on spirometric evidence of airways obstruction following bronchodilator administration. Although it used to be commonly believed that patients with COPD have largely irreversible airflow obstruction, evidence now suggests that a considerable proportion of patients exhibit clinically significant bronchodilator reversibility. The complexity and inherent variability of a patient s acute response to a bronchodilator and the lack of a standardized procedure for assessing bronchodilator reversibility have led to significant confusion surrounding this concept. Although bronchodilator reversibility commonly is defined based on thresholds for improvement in, lung volume-based measures of pulmonary function may be of particular importance in patients with severe COPD. The usefulness of acute reversibility to short-acting bronchodilators in predicting a patient s long-term response to bronchodilator maintenance therapy is also unclear, although most studies suggest that a lack of acute response to short-acting bronchodilators does not preclude a beneficial long-term response to maintenance bronchodilator treatment. This review outlines recent findings about the prevalence and usefulness of bronchodilator reversibility in patients with COPD based on the available literature and proposes areas of future research. CHEST 2011; 140(4): Abbreviations: ACCP 5 American College of Chest Physicians; ATS 5 American Thoracic Society; DPI 5 dry powder inhaler; ERS 5 European Respiratory Society; GOLD 5 Global Initiative for Chronic Obstructive Lung Disease; IC 5 inspiratory capacity; MCID 5 minimal clinically important difference; MDI 5 metered-dose inhaler; pmdi 5 pressurized metered-dose inhaler; UPLIFT 5 Understanding Potential Long-term Impacts on Function with Tiotropium The American Thoracic Society (ATS)/European Respiratory Society (ERS) and the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines define COPD as a preventable and treatable disease characterized by airflow limitation that is not Manuscript received November 18, 2010; revision accepted April 3, Affiliations: From the Section of Pulmonary and Critical Care Medicine, Asthma Clinical Research Center (Dr Hanania), Baylor College of Medicine, Houston, TX; Division of Pulmonary and Critical Care Medicine (Dr Celli), Brigham and Women s Hospital, Harvard University, Boston, MA; Division of Pulmonary Disease and Critical Care Medicine (Dr Donohue), University of North Carolina at Chapel Hill, Chapel Hill, NC; and Clinical Research, Respiratory and Inflammation Therapeutic Area (Dr Martin), AstraZeneca LP, Wilmington, DE. Funding/Support: This work was funded by AstraZeneca LP. Correspondence to: Nicola A. Hanania, MD, FCCP, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030; hanania@bcm.tmc.edu. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( site/misc/reprints.xhtml ). DOI: /chest fully reversible. 1,2 Airflow limitation in COPD, defined as a postbronchodilator /FVC of, 0.70, is recommended by the GOLD guidelines for use in diagnosis, staging, and monitoring progression of COPD. 2 However, it should be noted that this spirometric cut-point has not been clinically validated and its use may result in overdiagnosis of COPD in older adults and underdiagnosis in younger adults. 2-4 Defining COPD based on an /FVC ratio less than the lower limit of normal may minimize misdiagnosis; however, widespread use of this criterion is hindered by the limited availability of postbronchodilator reference values. 2 The extent to which airflow obstruction is reversible following the acute administration of an inhaled short-acting bronchodilator is unclear in patients with COPD.5 Moreover, a standard definition of clinically relevant bronchodilator reversibility has not been established, and confusion exists surrounding its usefulness in confirming the diagnosis of COPD and its predictive value in determining long-term response CHEST / 140 / 4 / OCTOBER,

2 to treatment. Some factors contributing to this confusion include the following: (1) potential misdiagnosis of COPD when using an /FVC ratio of, 0.70 as the only spirometric criterion, (2) the use of different definitions for a clinically relevant response to bronchodilation and different methodologies for determining reversibility in clinical studies, (3) the inherent within-subject variability in response to bronchodilator treatment, (4) the lack of understanding of the effect of COPD severity on treatment response, and (5) the lack of standardization surrounding lung function measures other than (eg, lung volume-based measures) in assessing bronchodilator reversibility. In this review, we outline recent findings surrounding the measurement and usefulness of acute bronchodilator reversibility in patients with COPD based on the available evidence in the current literature. Future areas of research that may contribute to a better understanding of the concept of reversibility in patients with COPD are also discussed. Determination of Bronchodilator Reversibility Although no standard definition of acute bronchodilator reversibility exists, available definitions are based on the absolute or percentage improvements in, FVC, or both from baseline following bronchodilator administration ( Table 1 ). 2,6-9 In addition, the definitions for a clinically meaningful improvement in after long-term treatment may differ from the criteria used to determine acute bronchodilator reversibility. Although a minimal clinically important difference (MCID) for has not been established, evidence suggests that a change in trough of 100 ml can be perceived as significant by most patients with COPD. 10 The ATS/ERS Task Force suggests a range of values for the MCID from baseline in ( ml) and considers a change of 5% to 10% from baseline to be clinically important. 11 Currently there is no clear consensus as to which definition of acute bronchodilator reversibility should be universally adopted because several factors may influence the determination of bronchodilator reversibility ( Table 2 ). 2,9 Compared with patients with less severe COPD, patients with more severe COPD tend to have lower baseline values and may, therefore, have greater percentage changes from baseline in pulmonary function measures but smaller absolute improvements from baseline. 11 Thus, the use of the combined 12% and 200 ml criteria recommended by ATS/ERS guidelines, which incorporate a measure of absolute pulmonary function improvement, may provide a more comprehensive approach. 9 Furthermore, there is no agreement regarding the specific bronchodilator, dose, or method of bronchodilator administration that should be used to determine reversibility. 9 The ATS/ERS Task Force recommends using a short-acting b 2 -adrenoceptor agonist, such as albuterol, or an anticholinergic, such as ipratropium bromide, for reversibility testing. 9,12 The drug should be administered as four separate doses (100 mg/dose for albuterol or 40 m g/dose for ipratropium bromide) using a spacer device. 9,12 In addition, it is recommended that spirometry be performed 15 min following albuterol administration or 30 min following ipratropium bromide administration. 9,12 When determining acute bronchodilator reversibility to a specific study drug, the timing of spirometric testing following drug administration should be based on the reported time to onset for the drug used. 9 GOLD guidelines recommend using an adequate dose of bronchodilator (eg, 400 m g albuterol) to minimize variability. 2 Published clinical studies have used differing methodologies to determine acute bronchodilator reversibility, including different definitions of reversibility and different types and doses of drugs. In two studies including 726 and 411 patients with COPD, Bleecker et al 13 and Mahler et al, 14 respectively, defined bronchodilator reversibility based on an increase from baseline in of 12% and 200 ml (ATS criteria) 30 min after treatment with 180 m g of albuterol. In contrast, in the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial (N 5 5,993), reversibility was determined at baseline by assessing bronchodilation 30 min after administration of short-acting bronchodilators that would produce near-maximal bronchodilation: ipratropium metered-dose inhaler (MDI) 80 m g followed 60 min later by albuterol MDI 400 m g. 15 In that analysis, reversibility was assessed using three reported definitions for improvement in : (1) 12% and 200 ml increase from baseline (ATS), (2) 15% increase from baseline (American College of Chest Physicians [ACCP]), and (3) 10% increase in percentage predicted (ERS). 15 That analysis also assessed reversibility based on responsiveness in alone, FVC alone, and either or FVC using ATS criteria. 15 In a more recent post hoc analysis of data pooled from common treatment arms in two other clinical studies in patients with moderate to very severe COPD, 16,17 reversibility was assessed 15 to 30 min after the administration of albuterol at screening and within 30 or 60 min after administration of the study drug (one of the following: budesonide/formoterol pressurized metered-dose inhaler [pmdi] 160/4.5 mg 3 2 inhalations [320/9 mg], budesonide/formoterol pmdi 80/4.5 mg 3 2 inhalations [160/9 m g], or formoterol dry powder inhaler [DPI] 4.5 m g 3 2 inhalations [9 m g]) on the day of randomization. 18 In that analysis, reversibility was also determined based on improvements in FVC or 1056 Special Features

3 Table 1 Common Criteria Used to Assess Acute Bronchodilator Reversibility Guideline Criteria ATS 6 FEV 1 or FVC improvement from predose value by 12% and 200 ml GOLD 2 improvement from predose value by. 12% and. 200 ml ERS7 Percentage predicted improvement from predose value by 10% ACCP8 improvement from predose value by 15% ATS/ERS9 FEV 1 and/or FVC improvement from predose value by. 12% and. 200 ml Data from References 2, 6-9. ACCP 5 American College of Chest Physicians; ATS 5 American Thoracic Society; ERS 5 European Respiratory Society; GOLD 5 Global Initiative for Chronic Obstructive Lung Disease. inspiratory capacity (IC) of 12% and 200 ml 1 h after administration of the study drug. 18 The lack of a standard criterion for defining and determining reversibility leads to difficulties in interpreting and comparing the results of acute reversibility tests across studies because reversibility status is affected by the improvement threshold 19 and the specific bronchodilator used. 20 In a study by Calverley et al, 19 42% of patients with COPD (n 5 660) showed reversibility to albuterol 400 m g followed 30 min later by ipratropium 80 m g administered via a spacer based on the combined ATS threshold ( 12% and 200 ml improvement in ). However, based on the ERS criterion ( 10% improvement in predicted ), only 23% of the patients exhibited reversibility. 19 Another study (n 5 813) evaluating reversibility in patients with COPD showed differences in the percentage of patients exhibiting reversibility based on an improvement in of 12% or 200 ml when different bronchodilators were used: 11% with ipratropium, 27% with albuterol, and 35% with ipratropium and albuterol. 20 Within-Subject Variability in Bronchodilator Reversibility The interpretation of acute reversibility findings is also complicated by the inherent variability in patient-level factors. Considerable variation exists in bronchodilator response over time. 21 In a study by Calverley et al, 19 reversibility status changed with subsequent study visits in 52% and 38% of patients based on the ATS threshold and the ERS criterion, respectively. Anthonisen and Wright 21 reported withinand between-subject variability in the annual percentage change in of 11.1% and 11.0%, respectively, after 250 m g of isoproterenol over 2.5 to 3 years. In that study, a correlation between variability in bronchodilator response and the patient s baseline value was reported. 21 In patients with lower baseline values, variability in response tended to be greater when expressed as a percentage change from prebronchodilator levels but smaller when expressed as a volume difference between prebronchodilator and postbronchodilator values. 21 Meanwhile, overall variability in response tended to be greater in patients with higher baseline values. 21 Changes in reversibility status using the ATS or ERS criteria after treatment with albuterol 400 mg followed 30 min later by ipratropium 80 m g also have been observed with repeated testing over time and were reported to be associated with changes in the prebronchodilator value. 19 Evidence also suggests that within-subject daily variation in the change in occurs in response to the same bronchodilator. 22 The extent of bronchodilator reversibility may also be affected by other medications taken before reversibility testing and the duration for which they were withheld. It is generally recommended that patients abstain from taking short-acting bronchodilators and caffeine-containing products for at least 6 h before bronchodilator reversibility testing. 2,21 Long-acting bronchodilators should be withheld for a longer period (12 to 24 h). 2,21 Finally, reversibility determination based only on improvements in may result in an underestimate of bronchodilator responsiveness. The inclusion of lung volume-based measures (eg, IC) may be more sensitive and may provide a more comprehensive assessment of reversibility in patients with COPD, particularly those with severe disease, as outlined following. 23 Bronchodilator Reversibility in COPD FEV 1 It is believed that patients with COPD have considerably less reversible airflow obstruction than patients with asthma, and this concept was, for a long time, inappropriately used to differentiate one disease from the other. 5 Evidence now suggests that patients with COPD indeed can also show significant reversibility following acute bronchodilator administration 13-15,18,24 and that reversibility testing may not be sensitive Table 2 Factors That May Influence the Determination of Acute Bronchodilator Reversibility in Patients With COPD Criterion used to define reversibility Baseline Dose and type of bronchodilator used to assess reversibility Prior use of bronchodilator(s) Timing of reversibility testing following bronchodilator administration Delivery technique Data from References 2, 9. CHEST / 140 / 4 / OCTOBER,

4 or specific enough to differentiate asthma from COPD. 25 In a post hoc analysis of two randomized, double-blind, parallel-group studies of patients aged 40 years with COPD and no prior history of asthma, Bleecker et al 13 assessed the efficacy of fluticasone/salmeterol 250/50 m g bid compared with four-times-daily treatment with ipratropium/albuterol 36/206 m g according to initial bronchodilator reversibility status at screening. Of the 726 patients, 44% exhibited reversibility based on ATS criteria.13 Likewise, Mahler et al 14 assessed the efficacy of salmeterol 42 m g bid compared with ipratropium 36 m g administered four times daily or placebo according to bronchodilator reversibility status in patients with COPD and no known history of asthma or other chronic respiratory disease other than COPD in a 12-week randomized, double-blind study. Of the 411 patients enrolled, approximately 65% showed reversibility based on ATS criteria. 14 The UPLIFT study measured bronchodilator reversibility following ipratropium and albuterol administration to produce near-maximal bronchodilation using the three criteria as discussed previously. 15 In that study, more than half of the patients exhibited bronchodilator reversibility in based on ATS and ACCP criteria, whereas 39% showed reversibility based on the ERS criterion ( Fig 1 ; criteria defined in Table 1 ). 15 As described earlier, bronchodilator reversibility was assessed recently in a post hoc analysis of data pooled from common treatment arms in a 6-month study 16 and a 12-month study 17 that included patients with moderate to very severe COPD. 18,24 At the screening visit, 34% to 39% of patients exhibited acute reversibility to albuterol based on ATS criteria, 18 whereas 51% to 54% of patients showed acute reversibility within 30 min to formoterol-containing treatment (budesonide/formoterol pmdi or formoterol DPI), 18 based on the same criteria on the day of randomization. When using the GOLD-recommended thresholds for classifying COPD severity (mild: 80% predicted ; moderate: 50% to, 80% predicted ; severe: 30% to, 50% predicted ; and very severe:, 30% predicted ), 2 bronchodilator reversibility (measured by changes in ) generally decreases as COPD severity increases. In the analysis reported by Bleecker et al, 13 the group of patients classified as nonreversible (n 5 399) at baseline comprised more patients who had GOLD stage III (severe; 45%) or IV (very severe; 12%) COPD compared with the group classified as reversible (n 5 320) (III, 40%; IV, 4%). Tashkin et al 15 reported a decrease in the percentage of patients who exhibited bronchodilator reversibility following ipratropium and albuterol administration with increasing COPD severity when using ATS criteria, but a similar percentage of patients Figure 1. Percentage of patients exhibiting reversibility to different thresholds for improvements in the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study at baseline. ACCP 5 American College of Chest Physicians; ATS 5 American Thoracic Society; ERS 5 European Respiratory Society. (Reprinted with permission from Tashkin et al. 15 ) exhibited bronchodilator reversibility across COPD severity categories when using the ACCP criterion ( Fig 2 ). Similar observations were noted following formoterol-containing treatment in the previously mentioned post hoc analyses of the 6-month and 12-month studies. 24 However, a considerable percentage of patients with GOLD stage IV COPD still met ATS criteria for bronchodilator reversibility following ipratropium and albuterol treatment (approximately 20%; Fig 2 ) 15 or formoterol-containing treatment (31%-41%). 18 It should be noted that the GOLDrecommended threshold values for COPD severity are not clinically validated, 2 and some overlap may exist between severity categories due to intraindividual and interindividual variation in percent predicted values. Further to this point, Weatherall et al 26 proposed using cut-off values of 80%, 60%, and 40% (instead of the GOLD-recommended thresholds of 80%, 50%, and 30%) based on similar magnitudes of change in St. George Respiratory Questionnaire scores between severity categories. The uncertainty surrounding the criteria that should be used for COPD severity classification hinders a definitive assessment of reversibility status by COPD severity category. Notably, improvements in pulmonary function following bronchodilator administration have also been demonstrated in healthy subjects, 27 and this bronchodilator responsiveness has been shown to decrease with age in healthy subjects. 27 Johannessen et al 27 reported mean changes in of 115 to 145 ml, 56 to 78 ml, and 34 to 46 ml 15 min after administration of 0.3 mg of albuterol DPI in healthy subjects aged 37 to 39, 40 to 59, and 60 to 82 years, respectively. Therefore, one limitation of most of the analyses described earlier is that they did not use postbronchodilator reference values or lower limit of normal when diagnosing COPD or adjust for patient age when assessing bronchodilator reversibility ,18,24 Data from 1058 Special Features

5 Figure 2. Percentage of patients demonstrating reversibility based on improvements in by COPD severity with ipratropium 80 m g and albuterol 400 m g in the UPLIFT study using the ATS or ACCP criteria. GOLD 5 Global Initiative for Chronic Obstructive Lung Disease. See Figure 1 legend for expansion of the other abbreviations. (Reprinted with permission from Tashkin et al. 15 ) a post hoc analysis of the UPLIFT trial in patients with COPD showed a significant ( P,.0001) difference in age between poorly responsive (65.1 years) and responsive patients (64.0 years) when using the combined ATS criteria for reversibility; however, differences between the two groups were not significant when using criteria of 15% for or 10% predicted. 15 Further research is warranted to assess the effects of age on reversibility in patients with and without COPD; however, available data generally suggest that patients with COPD can demonstrate significant acute bronchodilator reversibility ,18,24 Lung Volumes Lung volume-based measures of pulmonary function contribute important information about a patient s responsiveness to bronchodilator treatment. Findings have shown that patients who do not meet the threshold for reversibility based on may show considerable improvements in lung volume measurements, 15,23,28 with this effect being more pronounced with increasing COPD severity. 15 Moreover, improvements in IC correlate with improvements in exercise tolerance and endurance, 29,30 which are recognized as important goals of disease management. 2 A retrospective analysis of 957 patients aged 55 years with moderate or severe hyperinflation showed that in patients with severe hyperinflation (n 5 281; total lung capacity. 133% predicted and /FVC ratio, 85% predicted), only 11% showed reversibility to albuterol based on ATS criteria, whereas 26% exhibited reversibility based on IC (improvement of 10% predicted and 200 ml) and 53% based on FVC (ATS criteria). 28 Similarly, results from a study of 168 men with COPD showed that 34% of patients who did not exhibit bronchodilator reversibility in had reversibility in FVC after albuterol administration based on ATS criteria. 23 Additionally, Tashkin et al 15 reported that 49% of patients with GOLD stage IV (very severe) COPD exhibited a significant FVC response to ipratropium and albuterol treatment without showing a significant response based on ATS criteria; this percentage was only 5% in patients with GOLD stage II (moderate) COPD. Hence, assessing bronchodilator reversibility based on lung volume-based measures of pulmonary function in addition to may be important, particularly in patients with more severe COPD. The magnitude of observed improvements in FVC or IC after bronchodilator treatment also suggests that patients with COPD experience a clinically relevant bronchodilator response. In a post hoc analysis of data from the UPLIFT study, an increase in FVC from baseline of 471 ml (20.1%) was observed after ipratropium and albuterol treatment on the day of randomization. 15 In a 4-week randomized, double-blind, placebo-controlled study of 81 patients with COPD, treatment with tiotropium 18 m g daily resulted in significant ( P,.01) differences from placebo in peak FVC (480 ml) and IC (350 ml) after 4 weeks of treatment. 31 In addition, greater improvements in FVC and IC were observed after formoterol-containing treatments (budesonide/formoterol pmdi 320/9 mg, budesonide/formoterol pmdi 160/9 m g, and formoterol DPI 9 m g) compared with placebo (FVC ml vs 100 ml, respectively; IC ml vs 100 ml, respectively) on the day of randomization. 18 Overall, these findings show that patients with COPD exhibit considerable improvements in lung volume-based measures of pulmonary function after bronchodilator treatment. However, despite the importance of lung volume-based measures of pulmonary function, the US Food and Drug Administration recommends using as the primary efficacy end point in clinical studies assessing COPD medications and does not recommend lung volume-based measures as a primary measure of efficacy. 32 This preference for assessment of rather than FVC or IC in clinical trials include the following: (1) greater variability with lung volume-based measures compared with, 33 (2) lack of established MCID values for lung volume-based measures, 11 (3) lack of standardized testing procedures across study centers, (4) lack of established reference values for lung volume-based measures, (5) insufficient experience with lung volumebased measures in large clinical trials to enable large data sets to be scrutinized, and (6) increased effort to obtain lung volume-based measures as they may CHEST / 140 / 4 / OCTOBER,

6 require referral to a pulmonary function laboratory.11 Therefore, although lung volume-based measures provide important information about pulmonary function, these measures should be performed in conjunction with measurement. Therapeutic Implications of Bronchodilator Reversibility Another misconception about the usefulness of the acute bronchodilator reversibility is that patients with COPD who exhibit poor or no acute bronchodilator reversibility are not good candidates for long-term treatment with bronchodilators. This has been shown repeatedly to be inaccurate, although patients who exhibit acute reversibility to study medication or shortacting bronchodilators at baseline usually exhibit greater long-term improvements in pulmonary function than those classified as nonresponders. 14,34 Several studies have now shown that lack of an initial response to a short- or long-acting bronchodilator does not preclude subsequent benefit from maintenance bronchodilator therapy. 14,34 Thus, current guidelines no longer recommend using reversibility testing with a short-acting bronchodilator to predict longterm response to treatment. 2,9 In a post hoc analysis reported by Bleecker et al, 13 improvements in pulmonary function were observed with fluticasone/salmeterol 250/50 m g bid or ipratropium/albuterol 36/206 m g four times daily at baseline and week 8 in both reversible and nonreversible patients ( Fig 3 ). Although pulmonary function improvements were greater in reversible than nonreversible patients, improvements in dyspnea and COPD symptom scores generally were similar in both groups. 13 Similarly, Mahler et al 14 reported improvements in pulmonary function with both salmeterol administered bid and ipratropium administered four times daily in reversible and nonreversible patients ( Fig 4 ). Salmeterol treatment showed more sustained bronchodilation over 12 h compared with ipratropium treatment, with the decline in pulmonary function before the administration of the next dose of ipratropium (at 6 h) suggesting that ipratropium has a shorter duration of action. 14 The magnitude of bronchodilator response to salmeterol or ipratropium treatment over 12 h was greater in the reversible group compared with the nonreversible group at the end of 12 weeks. 14 However, nonreversible patients did show significantly greater improvements in pulmonary function with salmeterol or ipratropium treatment compared with placebo. 14 The magnitude of improvement in the UPLIFT analysis was greater in patients classified as responsive compared with those classified as poorly responsive, regardless of the criterion used. 15 Results Figure 3. Mean AUC on day 1 and after 8 weeks of treatment with FSC or IB/ALB by reversibility status at screening based on ATS criteria for improvement in. * P,.001 vs IB/ALB; P,.001 vs FSC; P.002 for week 8 vs day 1; ** P.01 for week 8 vs day 1. AUC 5 area under the curve; FSC 5 fluticasone/salmeterol combination; IB/ALB 5 ipratropium bromide/ albuterol. See Figure 1 legend for expansion of other abbreviation. (Reprinted with permission from Bleecker et al. 13 ) from a post hoc analysis of data from 5,783 patients in this study showed that both reversible and nonreversible patients experienced significant ( P,.005) improvements in postbronchodilator, FVC, and health-related quality of life (St. George Respiratory Questionnaire total score) and reductions in COPD exacerbations with tiotropium compared with placebo when using the ATS or ACCP criterion for reversibility. 35 Consistent with the data described previously, the ATS/ERS guidelines recommend that patients who do not demonstrate acute bronchodilator reversibility based on or FVC criteria should not be deprived of a 1- to 8-week trial on bronchodilator medication. 9 Future Needs Although current COPD guidelines recommend against using reversibility testing to predict a patient s long-term response to therapy, 2 these tests continue to be used in such capacities in clinical practice. Therefore, it is important to further explore the clinical implications of acute bronchodilator reversibility status in patients with COPD and to facilitate standardization of definitions and methods for reversibility testing. Current thresholds based on percentage improvements in can exaggerate the bronchodilator response in patients with a low baseline value. The ATS criterion, which includes an absolute improvement threshold of 200 ml in addition to the 12% threshold, may minimize this effect. 6 Future studies should explore associations between reversibility based on the ATS criteria and clinical benefits based on measures that are statistically derived (eg, improvements in symptom scores, COPD exacerbations, and pulmonary function). In addition, as 1060 Special Features

7 Figure 4. A, Change from baseline in over 12 h after 12 weeks of treatment with salmeterol, ipratropium, or placebo in patients classified as reversible. B, Change from baseline in over 12 h after 12 weeks of treatment with salmeterol, ipratropium, or placebo in patients classified as nonreversible. * P.026 vs placebo; 1 Significant differences between salmeterol and ipratropium. 14 (Reprinted with permission from Mahler et al. 14 ) greater focus is placed on patient-reported outcomes in COPD, associations between these measures and acute bronchodilator reversibility should be explored. The precise role of acute reversibility testing in the dose-finding phase of drug discovery, in particular with respect to bronchodilators, should also be explored. Although many patients with COPD demonstrate reversibility, approximately one-half fail to meet ATS criteria These findings may be relevant to population selection in dose-finding studies. Although high doses of the drug may be associated with greater adverse effects, the dose response may be shifted in less-reversible patients with COPD who may need higher doses to achieve clinical benefit. Evidence also suggests that results of reversibility testing may differ depending on the COPD severity category. Future studies should evaluate the clinical relevance of results of reversibility testing using the different available criteria with respect to other important measures, such as quality of life, exercise capacity, and symptoms, across all COPD severity categories. Future standardized methods for defining bronchodilator reversibility should also include guidance for selecting the drug, dose, and timing of reversibility testing after bronchodilator administration. Bronchodilator reversibility is commonly assessed based solely on criteria for improvements. 2,7,36 The ATS/ERS Task Force recommends the inclusion of FVC in assessing bronchodilator responsiveness. 9 Improvements in FVC may be clinically important, as they often correlate with improvements in exercise tolerance and endurance. 29,30 The need for the inclusion of IC in reversibility testing should also be explored because improvements in IC have been shown to correlate with improvements in dyspnea, 37 and the ratio of IC as a function of total lung capacity is an independent predictor of risk of death over time. 38 It is important to note that differences in the quality of patients spirometry technique may exist between clinical trials and real world clinical practice, with poorer technique leading to underestimation of, IC, and FVC. 39 Patients participating in clinical trials may undergo more extensive spirometry training and observation compared with patients in clinical practice, and clinical trials typically exclude patients who are unable to perform spirometry testing properly. These factors should be considered when interpreting reversibility data from clinical trials. Future research in patients with varying disease severity is warranted to further evaluate the clinical relevance and generalizability of these findings, and standardization of methods for measuring lung volumes and further research identifying MCIDs for lung volume-based measures are needed. Summary Patients with COPD were traditionally believed to have largely irreversible airway obstruction, and the acute reversibility status was often used to differentiate between COPD and asthma. However, recent studies demonstrate that many patients with COPD do indeed exhibit bronchodilator reversibility 13-15,18,24 and that reversibility testing is not a reliable measure to differentiate between asthma and COPD. 2,25 Several factors may influence bronchodilator reversibility, including disease severity, criteria used to define reversibility, and method and drug used for reversibility testing. Evidence also suggests that reversibility results can change with repeated testing in the same individual and do not predict a patient s longterm response to maintenance bronchodilator treatment. 14,34 Future research should explore the clinical relevance of the acute reversibility findings based on different criteria with respect to other important clinical outcomes, such as quality of life, exercise capacity, and dyspnea, in patients with COPD across a range of severity categories. CHEST / 140 / 4 / OCTOBER,

8 Acknowledgments Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Hanania has received research grant support from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Novartis, and Pfizer and has served as a consultant for GlaxoSmithKline, Novartis, and Pfizer and on the Speakers Bureaus of GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca. Dr Celli has served as a consultant or on the advisory boards for AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline and has received industry-sponsored grants from AstraZeneca, Boehringer Ingelheim, and Pfizer. Dr Donohue has received grant monies from Boehringer Ingelheim, Novartis, Johnson & Johnson, National Institutes of Health, and Alpha-1 Foundation, has served as a consultant for Novartis, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, and Merck, and has participated in speaking activities for Boehringer Ingelheim, Pfizer, GlaxoSmithKline, and AstraZeneca. Dr Martin is an employee of and owns stock in AstraZeneca LP. Role of sponsors : AstraZeneca LP (Wilmington, Delaware) provided funding for writing assistance from Scientific Connexions (Newtown, Pennsylvania). Other contributions: We thank Anny Wu, PharmD, and Cynthia Gobbel, PhD, from Scientific Connexions (Newtown, Pennsylvania) for writing assistance funded by AstraZeneca LP (Wilmington, Delaware). References 1. Celli BR, MacNee W ; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J ; 23 ( 6 ): Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated Accessed May 19, Vollmer WM, Gíslason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J ;34(3): García-Rio F, Soriano JB, Miravitlles M, et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest ;139(5): Lynes D, Frankland K. Reversibility testing in patients with asthma and COPD. Nurs Stand ;23(3): American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis ;144(5): Siafakas NM, Vermeire P, Pride NB, et al ; The European Respiratory Society Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J ;8(8): Report of the Committee on Emphysema American College of Chest Physicians. Criteria for the assessment of reversibility in airways obstruction. Chest ;65(5): Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J ; 26 ( 5 ): Donohue JF. Minimal clinically important differences in COPD lung function. COPD ;2(1): Cazzola M, MacNee W, Martinez FJ, et al ; American Thoracic Society ; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J ;31(2): Miller MR, Hankinson J, Brusasco V, et al ; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J ;26(2): Bleecker ER, Emmett A, Crater G, Knobil K, Kalberg C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther ;21 (4 ): Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest ; 115 (4 ): Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J ; 31 (4 ): Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metereddose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs ;68 (14 ): Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs ;69 (5 ): Celli BR, Tashkin DP, Rennard SI, et al. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pmdi in COPD [published online ahead of print April 28, 2011]. Respir Med. doi: /j.rmed Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax ;58 (8 ): Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest ; 126 ( suppl 2 ): 125S - 137S. 21. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis ;133 (5 ): BMJ Publishing Group Ltd and British Thoracic Society. Diagnosing COPD. Thorax ;59 (suppl 1 ):i27-i Ben Saad H, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther ;21 (5 ): Tashkin DP, Celli BR, Rennard SI, et al. Bronchodilator responsiveness to formoterol (FM)-containing treatments by chronic obstructive pulmonary disease (COPD) severity classification [abstract]. J Allergy Clin Immunol ; 125 (2 ):AB Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest ; 105 ( 4 ): Weatherall M, Marsh S, Shirtcliffe P, Williams M, Travers J, Beasley R. Quality of life measured by the St George s Respiratory Questionnaire and spirometry. Eur Respir J ;33 (5 ): Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med ;173 (12 ): Newton MF, O Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest ;121 (4 ): Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J ;16 (2 ): O Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med ;158 (5 pt 1 ): Special Features

9 31. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest ;124 (5 ): Guidance for Industry. Chronic obstructive pulmonary disease: developing drugs for treatment. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. downloads/drugs GuidanceComplianceRegulatoryInformation/ Guidances/ucm pdf. Published November Accessed April 21, Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D. Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol ;59 (4 ): Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest ;123 (5 ): Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res ;12(1): Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest ; 121 (5 suppl ):121S-126S. 37. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J ;21 (1 ): Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med ;171 (6 ): Global Initiative for Chronic Obstructive Lung Disease (GOLD). Spirometry for health care providers. pdf/gold%20spirometryfull[1].pdf. Accessed January 12, CHEST / 140 / 4 / OCTOBER,

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

Bronchodilator responsiveness and onset of effect with budesonide/formoterol pmdi in COPD

Bronchodilator responsiveness and onset of effect with budesonide/formoterol pmdi in COPD Respiratory Medicine (2011) 105, 1176e1188 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Bronchodilator responsiveness and onset of effect with budesonide/formoterol

More information

Chronic obstructive pulmonary disease (COPD) is characterized

Chronic obstructive pulmonary disease (COPD) is characterized DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment

More information

Bronchodilator responsiveness in patients with COPD

Bronchodilator responsiveness in patients with COPD Eur Respir J 28; 31: 742 75 DOI: 1.1183/931936.12967 CopyrightßERS Journals Ltd 28 Bronchodilator responsiveness in patients with COPD D.P. Tashkin*, B. Celli #, M. Decramer ", D. Liu +, D. Burkhart +,

More information

Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance

Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance Eur Respir Rev 2006; 15: 99, 37 41 DOI: 10.1183/09059180.00009903 CopyrightßERSJ Ltd 2006 Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance D.E. O Donnell ABSTRACT: The

More information

The physiological hallmark of chronic. Tiotropium as essential maintenance therapy in COPD. M. Decramer

The physiological hallmark of chronic. Tiotropium as essential maintenance therapy in COPD. M. Decramer Eur Respir Rev 2006; 15: 99, 51 57 DOI: 10.1183/09059180.00009906 CopyrightßERSJ Ltd 2006 Tiotropium as essential maintenance therapy in COPD M. Decramer ABSTRACT: Over the past decade, several large-scale

More information

SHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2

SHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2 SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative

More information

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Eur Respir J 2002; 19: 639 644 DOI: 10.1183/09031936.02.00238002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Pharmacodynamic steady state

More information

QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY

QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY ERJ Express. Published on January 22, 2009 as doi: 10.1183/09031936.00116808 QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY 1 Mark Weatherall, 2 Suzanne Marsh, 2 Philippa

More information

Shaping a Dynamic Future in Respiratory Practice. #DFResp

Shaping a Dynamic Future in Respiratory Practice. #DFResp Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory

More information

Decramer 2014 a &b [21]

Decramer 2014 a &b [21] Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively

More information

Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD $

Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD $ Respiratory Medicine (2005) 99, 695 702 Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD $ Mathieu Molimard a,, Jacques Bourcereau b, Vincent Le Gros c, Isabelle

More information

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Pulmonary Pharmacology & Therapeutics

Pulmonary Pharmacology & Therapeutics Pulmonary Pharmacology & Therapeutics 31 (2015) 85e91 Contents lists available at ScienceDirect Pulmonary Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/ypupt Daily variation in

More information

Tolerance to bronchodilating effects of salmeterol in COPD

Tolerance to bronchodilating effects of salmeterol in COPD Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130

More information

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent

More information

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Send Orders of Reprints at bspsaif@emirates.net.ae 150 The Open Respiratory Medicine Journal, 2012, 6, 150-154 Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Charlotte Suppli

More information

External validity of randomized controlled trials in COPD

External validity of randomized controlled trials in COPD Respiratory Medicine (2007) 101, 1313 1320 External validity of randomized controlled trials in COPD Justin Travers a, Suzanne Marsh a, Brent Caldwell a, Mathew Williams a, Sarah Aldington a, Mark Weatherall

More information

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1 58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family

More information

Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients

Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients Yuan et al. BMC Pulmonary Medicine 2014, 14:16 RESEARCH ARTICLE Open Access Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients Wei

More information

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals

More information

The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study

The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study Respiratory Medicine (2007) 101, 957 962 The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study Mario Cazzola a,,1, Maria Gabriella Matera b a Department

More information

Mario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni, MD

Mario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni, MD Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD* Mario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni,

More information

In patients with symptomatic COPD, desirable. Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful?

In patients with symptomatic COPD, desirable. Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful? Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful? Denis E. O Donnell, MD, FCCP Bronchodilator therapy in COPD is deemed successful if it improves ventilatory mechanics to

More information

Several decades ago, the choices for the management

Several decades ago, the choices for the management A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol* James F. Donohue, MD, FCCP; Jan A. van Noord, MD, PhD; Eric

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

T he recent international guidelines from the Global

T he recent international guidelines from the Global 842 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study A Johannessen, E R Omenaas, P

More information

Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma

Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma ORIGINAL RESEARCH Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma Daphne C Richter 1 James R Joubert 1 Haylene Nell

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT

More information

COPD: Current Medical Therapy

COPD: Current Medical Therapy COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for

More information

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 2003; 21: 267 272 DOI: 10.1183/09031936.03.00068503a Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Minimal important difference

More information

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08 Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes

More information

BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW

BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers

More information

Comparing COPD Treatment: Nebulizer, Metered Dose Inhaler, and Concomitant Therapy

Comparing COPD Treatment: Nebulizer, Metered Dose Inhaler, and Concomitant Therapy The American Journal of Medicine (2007) 120, 435-441 CLINICAL RESEARCH STUDY Comparing COPD Treatment:, Metered Dose, and Concomitant Therapy Donald P. Tashkin, MD, a Gerald L. Klein, MD, b,c Shoshana

More information

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,

More information

Journal of the COPD Foundation

Journal of the COPD Foundation 132 Predictors of Change in SGRQ Score Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Baseline Severity as Predictor of Change in St George s Respiratory Questionnaire

More information

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES: TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY

More information

COPD is a progressive disorder leading to increasing

COPD is a progressive disorder leading to increasing Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD* Richard Casaburi, MD, PhD, FCCP; David Kukafka, MD, FCCP; Christopher B. Cooper,

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? AUTHOR COPY ORIGINAL RESEARCH Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Kian-Chung Ong 1 Suat-Jin Lu 1 Cindy Seok-Chin Soh 2 1 Department

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause

More information

Research Article Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD

Research Article Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD Pulmonary Medicine Volume 2011, Article ID 780215, 6 pages doi:10.1155/2011/780215 Research Article Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD Bernd Lamprecht,

More information

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebocontrolled

Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebocontrolled ERJ Express. Published on August 6, 2010 as doi: 10.1183/09031936.00045810 For: European Respiratory Journal Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebocontrolled comparison Oliver

More information

Treatment of COPD: the sooner the better?

Treatment of COPD: the sooner the better? 1 Respiratory Division, University of Leuven, Belgium 2 Respiratory Division, David Geffen School of Medicine, University of California, Los Angeles, USA Correspondence to Marc Decramer, Respiratory Division,

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium Eur Respir J 2; 15: 878±885 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 Long-term treatment of chronic obstructive pulmonary disease with

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

The FDA Critical Path Initiative

The FDA Critical Path Initiative The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and

More information

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease

More information

A meta-analysis on the efficacy of oral theophylline in patients with stable COPD

A meta-analysis on the efficacy of oral theophylline in patients with stable COPD ORIGINAL RESEARCH A meta-analysis on the efficacy of oral theophylline in patients with stable COPD Néstor A Molfino Peter Zhang Otsuka Maryland Research Institute, Rockville, MD, USA Background: Theophylline

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

C hronic obstructive pulmonary disease (COPD) is currently

C hronic obstructive pulmonary disease (COPD) is currently 659 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Bronchodilator reversibility testing in chronic obstructive pulmonary disease P M A Calverley, P S Burge, S Spencer, J A Anderson, P W Jones, for the ISOLDE Study

More information

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Respiratory Medicine (2006) 100, 2190 2196 Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Kang-Hoe

More information

Anticholinergic Medications for the Treatment of Chronic Obstructive Pulmonary Disease

Anticholinergic Medications for the Treatment of Chronic Obstructive Pulmonary Disease Anticholinergic Medications for the Treatment of Chronic Obstructive Pulmonary Disease Daren L. Knoell, PharmD ABSTRACT Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial

Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial Eur Respir J 2010; 35: 287 294 DOI: 10.1183/09031936.00082909 CopyrightßERS Journals Ltd 2010 Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial D.P. Tashkin*, B. Celli

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters

Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters European Review for Medical and Pharmacological Sciences 2005; 9: 209-215 Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters C. TERZANO, A. PETROIANNI,

More information

Epidemiology of COPD Prof. David M. Mannino, M.D.

Epidemiology of COPD Prof. David M. Mannino, M.D. Epidemiology of COPD David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health College of Public Health University of Kentucky 1 Outline Definitions Severity Progression

More information

Yuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh

Yuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh 2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna

More information

ADRB2 Polymorphisms and Budesonide/Formoterol Responses in COPD

ADRB2 Polymorphisms and Budesonide/Formoterol Responses in COPD CHEST Original Research ADRB2 Polymorphisms and Budesonide/Formoterol Responses in COPD Eugene R. Bleecker, MD, FCCP ; Deborah A. Meyers, PhD ; William C. Bailey, MD, FCCP ; Anne-Marie Sims, PhD ; Sarah

More information

Fixed combination therapies in COPD effect on quality of life

Fixed combination therapies in COPD effect on quality of life REVIEW Fixed combination therapies in COPD effect on quality of life Beatrix Groneberg-Kloft 1,2 Axel Fischer 2 Tobias Welte 1 1 Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany;

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

Chronic obstructive pulmonary disease (COPD) affects

Chronic obstructive pulmonary disease (COPD) affects PHARMACOLOGY NOTES Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease MARTHA C. DURHAM, PHARMD Tiotropium represents a new generation of inhaled

More information

Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes

Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes Patient Related Outcome Measures open access to scientific and medical research Open Access Full Text Article Review Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with

More information

Long Term Care Formulary RS -29

Long Term Care Formulary RS -29 RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)

More information

Spirometric Correlates of Improvement in Exercise Performance after Anticholinergic Therapy in Chronic Obstructive Pulmonary Disease

Spirometric Correlates of Improvement in Exercise Performance after Anticholinergic Therapy in Chronic Obstructive Pulmonary Disease Spirometric Correlates of Improvement in Exercise Performance after Anticholinergic Therapy in Chronic Obstructive Pulmonary Disease DENIS E. O DONNELL, MIU LAM, and KATHERINE A. WEBB Respiratory Investigation

More information

C hronic obstructive pulmonary disease is an unremitting

C hronic obstructive pulmonary disease is an unremitting 399 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD V Brusasco, R Hodder,

More information

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017 GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and

More information

UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures

More information

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Effect of N-Acetylcysteine on Air Trapping in COPD. A Randomized Placebo-Controlled Study

Effect of N-Acetylcysteine on Air Trapping in COPD. A Randomized Placebo-Controlled Study CHEST Effect of N-Acetylcysteine on Air Trapping in COPD A Randomized Placebo-Controlled Study David Stav, MD; and Meir Raz, MD Original Research COPD Background: FEV 1 is used for the classification of

More information

Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease $

Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease $ Respiratory Medicine (2004) 98, 591 597 Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease $ Kai Michael Beeh a, *, Oliver Kornmann

More information

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Spencer S, Evans DJ, Karner C, Cates CJ This is a reprint of a Cochrane review, prepared and

More information

Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking

Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Julia Korell (1), Steven W. Martin (2), Mats O. Karlsson (1), Jakob Ribbing (1,3) (1) Uppsala University, Sweden

More information

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids ORIGINAL RESEARCH Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids Richard Hodder 1 Steven Kesten 2 Shailendra Menjoge 2 Klaus Viel 3 1 Divisions

More information

copyright of the original publisher. and distribution prohibited.

copyright of the original publisher. and distribution prohibited. Dis Manage Health Outcomes 2007; 15 (2): 91-100 LEADING ARTLE 1173-8790/07/0002-0091/$44.95/0 2007 Adis Data Information BV. All rights reserved. The Role of Spirometry in Evaluating Therapeutic Responses

More information

Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,

Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,

More information

The TORCH (TOwards a Revolution in COPD Health) survival study protocol

The TORCH (TOwards a Revolution in COPD Health) survival study protocol Eur Respir J 2004; 24: 206 210 DOI: 10.1183/09031936.04.00120603 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 LAUNCHING NEW STUDIES The

More information

Objectives. Advances in Managing COPD Patients

Objectives. Advances in Managing COPD Patients 4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,

More information

-agonists (LABA) in chronic obstructive pulmonary disease: effi cacy and safety

-agonists (LABA) in chronic obstructive pulmonary disease: effi cacy and safety REVIEW Long-acting -agonists (LABA) in chronic obstructive pulmonary disease: effi cacy and safety Andrea Rossi 1 Sonia Khirani 1 Mario Cazzola 2 1 Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo,

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease Indacaterol Versus Tiotropium

Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease Indacaterol Versus Tiotropium Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease Indacaterol Versus Tiotropium James F. Donohue 1, Charles Fogarty 2, Jan Lötvall 3, Donald A. Mahler 4, Heinrich Worth 5, Arzu Yorgancioğlu

More information

Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during

Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during 2008-2012 Doi:10.5901/mjss.2013.v4n9p573 Abstract Alida Sina PhD Student, Health Insurance Institute, Tirana, Albania

More information

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical

More information

Research in Real Life

Research in Real Life Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary

More information

Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital

Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital ORIGINAL ARTICLE Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital ARM Fauzi, MRCP Kulliyah of Medicine, International Islamic

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information